Gapinski D M, Mallett B E, Froelich L L, Jackson W T
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285.
J Med Chem. 1990 Oct;33(10):2807-13. doi: 10.1021/jm00172a020.
A series of lipophilic benzophenone dicarboxylic acid derivatives were found to inhibit the binding of the potent chemotaxin leukotriene B4 (LTB4) to its receptor on intact human neutrophils. Activity at the LTB4 receptor was determined by using a [3H]LTB4-binding assay. The structure-activity relationship for the lipophilic side chain was systematically investigated. Compounds with n-alkyl side chains of varying lengths were prepared and tested. Best inhibition of [3H]LTB4 binding was observed with the n-decyl derivative. Analogues with alkyl chains terminated with an aromatic ring showed improved activity. The 6-phenylhexyl side chain was optimal. Substitution on the terminal aromatic ring was also evaluated. Methoxyl, methylsulfinyl, and methyl substituents greatly enhanced the activity of the compound. For a given substituent, the para isomer had the best activity. Thus the nature of the lipophilic side chain can greatly influence the ability of the compounds to inhibit the binding of LTB4 to its receptor on intact human neutrophils. The most active compound from this series, 84 (LY223982), bound to the LTB4 receptor with an affinity approaching that of the agonist.
发现一系列亲脂性二苯甲酮二羧酸衍生物可抑制强效趋化因子白三烯B4(LTB4)与其在完整人中性粒细胞上的受体的结合。通过使用[3H]LTB4结合试验来测定LTB4受体的活性。系统研究了亲脂性侧链的构效关系。制备并测试了具有不同长度正烷基侧链的化合物。正癸基衍生物对[3H]LTB4结合的抑制效果最佳。带有芳环末端的烷基链类似物显示出更高的活性。6-苯基己基侧链是最佳的。还评估了末端芳环上的取代情况。甲氧基、甲亚砜基和甲基取代基极大地增强了化合物的活性。对于给定的取代基,对位异构体具有最佳活性。因此,亲脂性侧链的性质可极大地影响化合物抑制LTB4与其在完整人中性粒细胞上的受体结合的能力。该系列中最具活性的化合物84(LY223982)与LTB4受体结合的亲和力接近激动剂。